Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline Review, H1 2020’, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia)

– The report reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Anemia in Chronic Kidney Disease (Renal Anemia) therapeutics and enlists all their major and minor projects

– The report assesses Anemia in Chronic Kidney Disease (Renal Anemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Akebia Therapeutics Inc

Amgen Inc

Apotex Inc

Bayer AG

Biocad

Cadila Healthcare Ltd

Chong Kun Dang Pharmaceutical Corp

Dong-A Socio Holdings Co Ltd

FibroGen Inc

FortuneRock (China) Ltd

Genexine Inc

GlaxoSmithKline Plc

Great Bay Bio

HEC Pharm Co Ltd

HK inno.N Corp

Japan Tobacco Inc

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Liminal BioSciences Inc

Panacea Biotec Ltd

Pangen Biotech Inc

PharmaEssentia Corp

PhytoHealth Corp

SunBio Inc

Taisho Pharmaceutical Holdings Co Ltd

UBI Pharma Inc

Xenetic Biosciences Inc

Zosano Pharma Corp

Table of Contents

Table of Contents

Introduction

Anemia in Chronic Kidney Disease (Renal Anemia) - Overview

Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Development

Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment

Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development

Anemia in Chronic Kidney Disease (Renal Anemia) - Drug Profiles

Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects

Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products

Anemia in Chronic Kidney Disease (Renal Anemia) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by 3SBio Inc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Akebia Therapeutics Inc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Amgen Inc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Apotex Inc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Bayer AG, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Biocad, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Cadila Healthcare Ltd, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Dong-A Socio Holdings Co Ltd, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by FibroGen Inc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by FortuneRock (China) Ltd, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Genexine Inc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by GlaxoSmithKline Plc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Great Bay Bio, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by HEC Pharm Co Ltd, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by HK inno.N Corp, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Japan Tobacco Inc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Liminal BioSciences Inc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Panacea Biotec Ltd, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Pangen Biotech Inc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by PharmaEssentia Corp, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by PhytoHealth Corp, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by SunBio Inc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by UBI Pharma Inc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Xenetic Biosciences Inc, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Pipeline by Zosano Pharma Corp, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Dormant Projects, H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Dormant Projects, H1 2020 (Contd..1), H1 2020

Anemia in Chronic Kidney Disease (Renal Anemia) – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports